Genetically predicted higher CD25++CD4+ T cell absolute count showed a reduction in MS susceptibility (OR [95%CI] = 0.75 [0.66,0.86], P = 2.12E-05, P adjust = 1.72E-03), as well as the proportion of CD25++CD4+ T cell in T cell (OR [95%CI] = 0.79[0.70,0.89], P = 8.54E-05, P adjust = 5.29E-03) and in CD4+ T cell (OR [95%CI] = 0.80[0.72,0.89], P = 1.85E-05, P adjust = 1.72E-03). This evidence concerns the gene CD4 and myeloid sarcoma.